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Letter to the EditorReduced mortality due to phlebotomy in moderately iron-loaded
HFE haemochromatosis? The need for clinical trialsTo the Editor:
We read with interest the paper by Bardou-Jacquet and col-
leagues [1] examining mortality in HFE-associated hemochro-
matosis and the accompanying editorial [2]. Both the authors of
the study and the writers of the editorial concluded that the
observation that HFE p.C282Y homozygotes with a serum ferritin
(SF) at diagnosis between the upper limit of normal (ULN) and
1000 lg/L have reduced mortality compared to the population
at large is predominantly due to venesection therapy.
We are not convinced however, that this conclusion is sup-
ported by the data provided for the following reasons:
1. If normalization of SF resulted in reduced mortality then it
would be expected that HFE p.C282Y homozygotes with nor-
mal SF at diagnosis would also have reduced mortality but this
was not found to be the case.
2. There was no information about the amount of iron removed
for 36% of subjects so there was likely to be a significant
minority of individuals with SF between the ULN and
1000 lg/L who did not have normalization of SF.
3. The cohort had a follow-up mean duration of 8.3 ± 3.9 years.
The average age at diagnosis was 45.2 ± 14.2 years. This means
that it is likely that many subjects in the group with SF
between the ULN and 1000 lg/L had a raised SF for many
more years than they had a normalized SF. It is not at all clear
how this balance would result in reduced mortality when this
was not seen among those with normal SF at diagnosis. Of
those who did have information about the amount of iron
removed, there is no information about whether they contin-
ued venesection therapy in order to maintain a SF level
<50 lg/L after a SF of <50 lg/L was achieved initially, or the
extent to which follow-up data (number and volume of phle-
botomies, clinical and biochemical indicators of tolerance and
efficacy of venesection therapy) were available. Moreover,
there is no information about a formal, standardized, consis-
tent, cohort-wide protocol around advising participants to
start, continue and potentially stop venesection therapy,
which makes the claim that the results can be interpreted as
‘‘intention-to-treat’’ difficult to justify.
Reasons other than the benefit of normalization of SF that
could explain the study findings include:
1. Having a mild excess of iron in the body reduces the risk of
cardiovascular and extra-hepatic cancer. This is counter intui-
tive with data suggesting that iron is a pro-oxidant and there-
fore more likely to result in increased cancer incidence. In
addition we found an increase in the incidence of breast and
colorectal cancer in a large cohort of HFE p.C282Y homozy-
gotes compared to a matched HFE wild-type control group,
we did not, however, have sufficient data to examine theJournal of Hepatology 20association of cancer occurrence with SF levels [3]. From the
cardiovascular standpoint, there is evidence that low hepcidin
levels that are associated with HFE p.C282Y homozygosity,
leads to low reticuloendothelial cell iron levels despite
high total body iron and that this can lead to reduced
levels of atherosclerosis (the so called ‘‘hemochromatosis
paradox’’) [4].
2. As noted by the authors, those with SF between the ULN and
1000 lg/L had increased medical care compared to the
average person and this may have resulted in other lifestyle
changes that were beneficial. For example lifestyle changes
in subjects with fatty liver disease such as diet and exercise,
can improve liver function and morbidity. No information is
given by the authors on body mass index and any changes
in this following appropriate intervention.
3. Individuals with SF between ULN and 1000 lg/L are less prone
to iron deficiency anemia and this may result in health benefit.
The only way to answer the question of the role of venesection
therapy in HFE p.C282Y homozygotes with SF between ULN and
1000 lg/L is to do a randomized study with half the cohort
having normalization of SF and the other half not being treated.
Until such data are available, the question of benefit from treating
HFE p.C282Y homozygotes with SF between ULN and 1000 lg/L
remains, in our view, unproven.Conflict of interest
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